Grant: CIHR Fellowship
Direct Payment
$150,000.00
Towards a Universal Influenza Virus Vaccine
FY 2011-12
Summary
Seasonal influenza A virus (IAV) outbreaks represent a significant burden to global healthcare systems. In Canada alone, there were over 39 000 reported cases of IAV during the 2009-2010 season. During the course of a normal season, IAV infections are responsible for 700-2500 deaths. However, rates of infection and mortality can increase greatly during periodic pandemics. The major natural hosts of IAV are aquatic birds, however the virus has been able to adapt well to infection of many mammalian species. Swine, in particular, are susceptible to infection by both avian and human IAVs, making them an important vessel for the generation of reassortant viruses that have the potential to cause serious disease in humans. IAV is also prone to rapid mutation. Together, these factors contribute to the ability of IAV to evade the immune system and cause seasonal disease. The haemagglutinin (HA) protein is the major target of the neutralizing antibody response to IAV. The globular head domain of this protein mutates readily and can then evade pre-existing immunity from prior immunization or infection. Recently, an invariant region has been discovered in the stalk domain of the HA protein. This domain is not normally antigenically predominant on the surface of the virus. However, recent studies by our group and others, have shown that immunization of mice with 'headless' HA protein can elicit a broadly neutralizing antibody response targeted to this conserved region of the HA stalk. Our current work will focus on refining these initial studies by testing multiple iterations of stalk domain-based peptides to determine which provide the greatest and most broadly-active protection. This work will contribute to the development of a vaccine which will have a major impact on the improvement of global health while eliminating the significant economic burder associated with seasonal IAV vaccination programs.
Department
Program
CIHR Fellowship
Recipient
Location
New York, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
242014
Name
Miller Matthew S
Region
New York
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Towards a Universal Influenza Virus Vaccine
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Antibodies; Host-Pathogen Interactions; Immunology; Influenza; Vaccine
Abstract
Seasonal influenza A virus (IAV) outbreaks represent a significant burden to global healthcare systems. In Canada alone, there were over 39 000 reported cases of IAV during the 2009-2010 season. During the course of a normal season, IAV infections are responsible for 700-2500 deaths. However, rates of infection and mortality can increase greatly during periodic pandemics. The major natural hosts of IAV are aquatic birds, however the virus has been able to adapt well to infection of many mammalian species. Swine, in particular, are susceptible to infection by both avian and human IAVs, making them an important vessel for the generation of reassortant viruses that have the potential to cause serious disease in humans. IAV is also prone to rapid mutation. Together, these factors contribute to the ability of IAV to evade the immune system and cause seasonal disease. The haemagglutinin (HA) protein is the major target of the neutralizing antibody response to IAV. The globular head domain of this protein mutates readily and can then evade pre-existing immunity from prior immunization or infection. Recently, an invariant region has been discovered in the stalk domain of the HA protein. This domain is not normally antigenically predominant on the surface of the virus. However, recent studies by our group and others, have shown that immunization of mice with 'headless' HA protein can elicit a broadly neutralizing antibody response targeted to this conserved region of the HA stalk. Our current work will focus on refining these initial studies by testing multiple iterations of stalk domain-based peptides to determine which provide the greatest and most broadly-active protection. This work will contribute to the development of a vaccine which will have a major impact on the improvement of global health while eliminating the significant economic burder associated with seasonal IAV vaccination programs.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Miller, Matthew S
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~